<DOC>
	<DOCNO>NCT02676986</DOCNO>
	<brief_summary>This study carry see antiandrogen enzalutamide antitumour effect early breast cancer . Enzalutamide block action androgen androgen receptor ( AR ) may slow stop breast cancer grow . Enzalutamide approve treatment prostate cancer . The trial offer patient diagnose early breast cancer plan surgery next week . The treatment bridge time diagnosis surgery give 2- 4 week . To assess effect treatment , small sample breast cancer tissue analyse start treatment . The pre-treatment assessment do archived tissue patient might require additional biopsy , sufficient store tumour tissue available . The end treatment sample take surgery , unless patient receive medical treatment first instead surgery might mean additional biopsy breast cancer take . The trial two cohort . The cohort patient oestrogen receptor ( ER ) positive breast cancer test add enzalutamide exemestane well slow growth breast cancer exemestane alone . This cohort recruit 141 evaluable post-menopausal patient tumour size least 1 cm . The aromatase inhibitor exemestane approve treatment ER positive breast cancer . Blocking aromatase decrease oestrogens increase androgen . Enzalutamide therefore add block action androgens AR . In second cohort patient triple negative breast cancer ( TNBC ) , enzalutamide give alone see slow growth tumour androgen receptor . As approximately 30 % TNBCs express AR , pre screen step include test tumour AR expression , patient approach ARB trial . The TNBC cohort comprise 55 patient .</brief_summary>
	<brief_title>Phase II Window Opportunity Study Short-term Preoperative Treatment With Enzalutamide ( Alone Combination With Exemestane ) Patients With Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Main 1 . Written inform consent prior admission study 2 . Female , age ≥18 year 3 . ECOG performance status 0 2 4 . Histologically confirm invasive primary breast cancer 5 . Palpable breast tumour size , tumour ultrasound MRI size least 1.0 cm 6 . Haematologic biochemical index within range show screen visit 1 . ANC 1500 cells/μl 2 . Platelet count 100000/μl 3 . Serum creatinine concentration &lt; 1.5 x ULN 4 . Bilirubin level &lt; 1.5 x ULN 5 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x ULN Inclusion Criteria unique ER+ve cohort : 1 . ER+ve tumour define ≥1 % tumour cell positive ER IHC stain IHC score ( Allred ) ≥3 2 . Postmenopausal define : 1 . Age 55 year 1 year amenorrhea 2 . Age 55 year 1 year amenorrhea LH and/or FSH level postmenopausal range 3 . Age 55 prior hysterectomy intact ovary LH and/or FSH level postmenopausal range 4 . Status bilateral oophorectomy ( 28 day prior first study treatment ) Inclusion Criteria unique AR+ve , TNBC cohort : 1 . AR positive tumour define nuclear AR stain IHC ( enrolment may base local pathology finding ; subsequent review AR expression central pathology laboratory carry ) 2 . Triplenegative tumour , i.e . tumour cell negative 1 . ER &lt; 1 % cell positive IHC IHC score ( Allred ) ≤2 2 . PR &lt; 1 % tumour cell positive IHC Allred score ≤2 3 . HER2 0 , 1+ 2+ intensity IHC evidence amplification HER2 gene ISH 3 . Negative serum urine pregnancy test woman childbearing potential within 2 week prior first dose study treatment , preferably close first dose possible . Patients childbearing potential must agree use adequate contraception ( example , intrauterine device [ IUD ] , birth control pills unless clinically contraindicate , barrier device ) begin 2 week first dose investigational medicinal product ( IMP ) 30 day final dose IMP . 1 . Inflammatory breast cancer 2 . Treatment follow medication within 4 week baseline diagnostic biopsy take : 1 . Oestrogens , include hormone replacement therapy ; 2 . Androgens ( testosterone , dihydroepiandrosterone , etc . ) ; 3 . Any approve investigational agent block androgen synthesis target AR ( e.g. , abiraterone acetate , ARN509 , bicalutamide , enzalutamide , ODM201 , TAK448 , TAK683 , TAK700 ) 3 . Previous systemic local treatment new primary breast cancer currently investigation ( include surgery , radiotherapy , cytotoxic endocrine treatment ) ; prior treatment previous breast cancer neoplasm allow long complete least 1 year prior inclusion trial . 4 . History seizure condition may predispose seizure ; history loss consciousness transient ischemic attack within 12 month day 1 . 5 . Significant cardiovascular disease , 1 . History myocardial infarction , acute coronary syndrome coronary angioplasty/stenting/bypass graft within past 6 month . 2 . Congestive heart failure New York Heart Association ( NYHA ) Class III IV history congestive heart failure NYHA class III IV , unless echocardiogram multigated acquisition scan perform within 3 month day 1 reveals leave ventricular ejection fraction ≥ 45 % ; 3 . History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsade de pointes ) ; 6 . Hypersensitivity active pharmaceutical ingredient excipients IMPs , include Labrasol , butylate hydroxyanisole , butylate Hydroxytoluene 7 . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory finding , investigator 's opinion , give reasonable suspicion disease condition contraindicate use IMP , may affect interpretation result , render patient high risk treatment complication interfere obtain informed consent . 8 . Psychological , familial , sociological geographical condition permit compliance study protocol . 9 . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 4 week prior study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Primary Breast Cancer</keyword>
	<keyword>ER</keyword>
	<keyword>AR</keyword>
	<keyword>TNBC</keyword>
</DOC>